MedTrace Logo

Lopinavir Capsules to Kaletra or Invirase Tablets

NCT00438152 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2011-07-18

No results posted yet for this study

Summary

This study will compare the benefit for patients switching from Kaletra® to Invirase® tablets over remaining on Kaletra® (based on randomization), to elicit the lipid benefits inferred in previous studies

Conditions

  • HIV Infections

Interventions

DRUG

Saquinavir (Invirase®)

Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks

DRUG

Lopinavir/ritonavir (Kaletra®)

Lopinavir/ritonavir 400/100 mg BD 24 weeks

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Royal Free Hampstead NHS Trust

    lead OTHER

Principal Investigators

  • Mike S Youle, MD MB ChB · Royal Free Hampstead NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00438152 on ClinicalTrials.gov